Tissue-specific promoters in gene therapy for the treatment of prostate cancer

T. Shirakawa, A. Gotoh, Y. Wada, S. Kamidono, S. C. Ko, C. Kao, T. A. Gardner, L. W.K. Chung

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic effect on neighboring normal cells when virus-mediated gene delivery results in their infection. We have demonstrated the utility of two prostate cancer- specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene therapy for bone metastases of prostate cancer, which is in progress at the University of Virginia.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalMolecular Urology
Volume4
Issue number2
DOIs
StatePublished - Jan 1 2000

Fingerprint

Poisons
Genetic Therapy
Prostatic Neoplasms
Osteocalcin
Androgens
Therapeutics
Genes
Neoplasm Metastasis
Viruses
Bone and Bones
Infection
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Shirakawa, T., Gotoh, A., Wada, Y., Kamidono, S., Ko, S. C., Kao, C., ... Chung, L. W. K. (2000). Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Molecular Urology, 4(2), 73-82. https://doi.org/10.1089/10915360050138620

Tissue-specific promoters in gene therapy for the treatment of prostate cancer. / Shirakawa, T.; Gotoh, A.; Wada, Y.; Kamidono, S.; Ko, S. C.; Kao, C.; Gardner, T. A.; Chung, L. W.K.

In: Molecular Urology, Vol. 4, No. 2, 01.01.2000, p. 73-82.

Research output: Contribution to journalArticle

Shirakawa, T, Gotoh, A, Wada, Y, Kamidono, S, Ko, SC, Kao, C, Gardner, TA & Chung, LWK 2000, 'Tissue-specific promoters in gene therapy for the treatment of prostate cancer', Molecular Urology, vol. 4, no. 2, pp. 73-82. https://doi.org/10.1089/10915360050138620
Shirakawa, T. ; Gotoh, A. ; Wada, Y. ; Kamidono, S. ; Ko, S. C. ; Kao, C. ; Gardner, T. A. ; Chung, L. W.K. / Tissue-specific promoters in gene therapy for the treatment of prostate cancer. In: Molecular Urology. 2000 ; Vol. 4, No. 2. pp. 73-82.
@article{d5164d7d67934e428395c86aa4c40cf5,
title = "Tissue-specific promoters in gene therapy for the treatment of prostate cancer",
abstract = "Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic effect on neighboring normal cells when virus-mediated gene delivery results in their infection. We have demonstrated the utility of two prostate cancer- specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene therapy for bone metastases of prostate cancer, which is in progress at the University of Virginia.",
author = "T. Shirakawa and A. Gotoh and Y. Wada and S. Kamidono and Ko, {S. C.} and C. Kao and Gardner, {T. A.} and Chung, {L. W.K.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1089/10915360050138620",
language = "English (US)",
volume = "4",
pages = "73--82",
journal = "Molecular Urology",
issn = "1091-5362",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Tissue-specific promoters in gene therapy for the treatment of prostate cancer

AU - Shirakawa, T.

AU - Gotoh, A.

AU - Wada, Y.

AU - Kamidono, S.

AU - Ko, S. C.

AU - Kao, C.

AU - Gardner, T. A.

AU - Chung, L. W.K.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic effect on neighboring normal cells when virus-mediated gene delivery results in their infection. We have demonstrated the utility of two prostate cancer- specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene therapy for bone metastases of prostate cancer, which is in progress at the University of Virginia.

AB - Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic effect on neighboring normal cells when virus-mediated gene delivery results in their infection. We have demonstrated the utility of two prostate cancer- specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene therapy for bone metastases of prostate cancer, which is in progress at the University of Virginia.

UR - http://www.scopus.com/inward/record.url?scp=0034046855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034046855&partnerID=8YFLogxK

U2 - 10.1089/10915360050138620

DO - 10.1089/10915360050138620

M3 - Article

C2 - 12006246

AN - SCOPUS:0034046855

VL - 4

SP - 73

EP - 82

JO - Molecular Urology

JF - Molecular Urology

SN - 1091-5362

IS - 2

ER -